Coronavirus-associated kidney outcomes in COVID-19, SARS, and MERS: a meta-analysis and systematic review by Zhou, S. et al.
This is a repository copy of Coronavirus-associated kidney outcomes in COVID-19, SARS,
and MERS: a meta-analysis and systematic review.




Zhou, S., Xu, J., Xue, C. et al. (3 more authors) (2021) Coronavirus-associated kidney 
outcomes in COVID-19, SARS, and MERS: a meta-analysis and systematic review. Renal 





This article is distributed under the terms of the Creative Commons Attribution (CC BY) licence. This licence 
allows you to distribute, remix, tweak, and build upon the work, even commercially, as long as you credit the 
authors for the original work. More information and the full terms of the licence here: 
https://creativecommons.org/licenses/ 
Takedown 
If you consider content in White Rose Research Online to be in breach of UK law, please notify us by 
emailing eprints@whiterose.ac.uk including the URL of the record and the reason for the withdrawal request. 
STATE OF THE ART REVIEW
Coronavirus-associated kidney outcomes in COVID-19, SARS, and MERS:
a meta-analysis and systematic review
Shoulian Zhoua, Jing Xua, Cheng Xuea, Bo Yangb, Zhiguo Maoa and Albert C. M. Ongc,d
aDivision of Nephrology, Changzheng Hospital, Second Military Medical University, Shanghai, People’s Republic of China; bInternal
Medicine III (Nephrology & Endocrinology), Naval Medical Center of PLA, Second Military Medical University, Shanghai, People’s
Republic of China; cAcademic Nephrology Unit, Department of Infection, Immunity and Cardiovascular Disease, University of Sheffield,
Sheffield, UK; dSheffield Teaching Hospitals NHS Trust, Sheffield Kidney Institute, Sheffield, UK
ABSTRACT
Objectives: A meta-analysis and systematic review was conducted on kidney-related outcomes
of three recent pandemics: SARS, MERS, and COVID-19, which were associated with potentially
fatal acute respiratory distress syndrome (ARDS).
Methods: A search of all published studies until 16 June 2020 was performed. The incidence/
prevalence and mortality risk of acute and chronic renal events were evaluated, virus prevalence,
and mortality in preexisting hemodialysis patients was investigated.
Results: A total of 58 eligible studies involving 13452 hospitalized patients with three types of
coronavirus infection were included. The reported incidence of new-onset acute kidney injury
(AKI) was 12.5% (95% CI: 7.6%–18.3%). AKI significantly increased the mortality risk (OR ¼ 5.75,
95% CI 3.75–8.77, p< 0.00001) in patients with coronavirus infection. The overall rate of urgent-
start kidney replacement therapy (urgent-start KRT) use was 8.9% (95% CI: 5.0%–13.8%) and
those who received urgent-start KRT had a higher risk of mortality (OR ¼ 3.43, 95% CI 2.02–5.85,
p< 0.00001). Patients with known chronic kidney disease (CKD) had a higher mortality than
those without CKD (OR ¼ 1.97, 95% CI 1.56–2.49, p< 0.00001). The incidence of coronavirus
infection was 7.7% (95% CI: 4.9%–11.1%) in prevalent hemodialysis patients with an overall mor-
tality rate of 26.2% (95% CI: 20.6%–32.6%).
Conclusions: Primary kidney involvement is common with coronavirus infection and is associ-
ated with significantly increased mortality. The recognition of AKI, CKD, and urgent-start KRT as
major risk factors for mortality in coronavirus-infected patients are important steps in reducing
future mortality and long-term morbidity in hospitalized patients with coronavirus infection.
ARTICLE HISTORY
Received 20 October 2020
Revised 2 November 2020





The novel coronavirus disease-2019 (COVID-19), first
reported in Wuhan, China, has become a worldwide
pandemic and has caused over 28,918,900 confirmed
cases of COVID-19 globally, including 922,252 deaths
reported to the World Health Organization (WHO) as of
3:28 pm CEST, 14 September 2020 [1]. Apart from the
rapid development of acute respiratory distress syn-
drome (ARDS), severe acute respiratory syndrome cor-
onavirus 2 (SARS-CoV-2), as well as the previously
identified severe acute respiratory syndrome
coronavirus (SARS-CoV-1) and Middle East respiratory
syndrome coronavirus (MERS-CoV), which are members
of the coronavirus family [2], also have major associated
but under-recognized extrapulmonary manifestations
[3–5]. These three types of coronaviruses have caused
catastrophic coronavirus pandemics in human history,
namely SARS, MERS, and COVID-19. Among the organs
affected, the kidneys are often involved due to the
organ cross-talk between alveolar and tubular damage,
i.e. the lung–kidney axis in ARDS [6]; the occurrence of
kidney involvement usually indicates a worse prognosis
[7,8]. Although the etiology of coronavirus-associated
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AKI is likely to be multifactorial, all three coronaviruses
can directly invade renal cells through hijacking native
surface receptors: angiotensin-converting enzyme 2
(ACE2) serves as a receptor for SARS-CoV-1 and SARS-
CoV-2 [9,10], while MERS-CoV enters target cells via
binding to dipeptidyl-peptidase 4 (DDP4) [11].
However, it is unclear how the virus causes cellular
damage following the entry. If maintained during the
course of infection, the kidney could function as a viral
reservoir and urine become a potential source of viral
transmission.
Acute kidney injury (AKI) is the most frequent extra-
pulmonary organ dysfunction associated with ARDS
and is an independent risk factor for mortality [12,13].
However, the reported prevalence and mortality of AKI
for all three coronavirus infection differs between stud-
ies. All patients with chronic kidney disease (CKD),
including those with end-stage kidney disease (ESKD)
or on kidney replacement therapy (KRT), are immuno-
suppressed making them more susceptible to infection
and potentially a more severe course [14–16]. The
potential increased risk related to preexisting CKD and
urgent-start KRT treatment is presently unclear. The
influence of SARS-CoV-2/COVID-19 on sustained dialysis
patients is also unknown.
In view of our previous experience with SARS, MERS,
and more recent experiences of the COVID-19 out-
breaks, we conducted a meta-analysis and systematic
review to investigate the kidney involvement and
patients’ outcomes in hospitalized coronavirus-
infected patients.
Methods
Data sources and search
This systematic review was performed following
PRISMA (Preferred Reporting Items for Systematic
Reviews and Meta-Analyses) guidelines. The registration
of this review was published in PROSPERO
(CRD42020200941). A search for published studies was
performed using the PubMed database, EMBASE, and
Cochrane library until 16 June 2020. Research articles
on coronavirus (SARS-CoV, MERS-CoV, and SARS-CoV2)
infected patients with information on kidney disease,
AKI, dialysis, or kidney function were eligible and
included. Keywords (‘COVID-190 OR ‘SARS-CoV2’) or
‘SARS-CoV’ or ‘MERS-CoV’ and (‘chronic kidney disease’
or ‘CKD’ or ‘kidney disease’ or ‘end-stage kidney dis-
ease’ or ‘ESKD’) or (‘acute kidney injury’ or ‘AKI’) or
(‘kidney replacement therapy’ or ‘KRT’ or ‘blood purifi-
cation’) or (‘dialysis’ or ‘hemodialysis’ or ‘blood purifica-
tion’) or (‘mortality’ or ‘death’) were combined to
construct corresponding search formulas in databases.
We used a combination of subject terms with free-text
terms during the search, supplemented by a manual
search and citation search. We also screened the latest
relevant articles about COVID-2019 and met the inclu-
sion criteria, through the "https://www.biorxiv.org/
search/covid-19" website.
Inclusion and exclusion criteria
Studies that met the following PICOS criteria were
included: (1) articles were original reports including
patients infected with coronavirus; (2) studies with out-
comes of interest consisting of mortality or kidney-
related outcomes, i.e. urgent-start KRT, AKI or dialysis;
(3) types of articles were cohort studies, case series, and
case-control studies. The exclusion criteria of the study
included articles reporting patients infected with cor-
onavirus other than SARS-CoV, MERS-CoV, and SARS-
CoV2; articles without relevant outcomes of interest;
commentaries or reviews; research articles with patient
numbers below five.
Study selection and data extraction
Two reviewers (ZS and XC) independently screened the
titles and abstracts and then checked the full text of all
the articles that might be eligible. Differences were
resolved through discussion or consultation with the
third reviewer (XJ). The two researchers separately
extracted data from the included studies, including first
author of the article, year, study design, follow-up,
number of reported cases, mortality, CKD, AKI, use of
urgent-start KRT, ESKD, incidence or mortality of
infected dialysis patients and related baseline character-
istics. Mortality was defined as the death of patients
during hospitalization.
The quality rating for each study was evaluated by
the NOS (Newcastle-Ottawa scale). For the evaluation of
case reports and case series included, we applied a gen-
erally recommended standard similar to NOS, based on
the domains of selection, ascertainment, causality and
reporting and provide signaling questions [17].
Patient and public involvement
No patient involved.
Certainty rating of evidence
The GRADE instrument (Grading of Recommendation,
Assessment, Development, and Evaluation) was applied
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to rate the certainty of evidence and the strength of
recommendations generated in our study [18–20]. The
certainty of evidence was rated for kidney-related com-
plications and underlying kidney diseases prevalence
and associations with patients’ prognosis. The five
GRADE considerations (study limitations, consistency of
effect, imprecision, indirectness and publication bias)
were taken into account to assess the confidence in
effect estimates. Quality of evidence was characterized
as high, moderate, low, or very low [20,21]. GRADE was
assessed per http://gradepro.org.
Statistical analysis
Assessment of risk of bias was performed by two
authors (XC and XJ) independently using the
Newcastle–Ottawa Quality Assessment Scale (NOS) [22].
Studies were scored up to a maximum of 9 points by
NOS. Study quality was classified into three categories:
0–3 (low), 4–6 (moderate), and 7–9 (high). Statistical
analyses were performed using Revman software V5.4
(Cochrane). Sensitivity analysis on the results of pooled
analysis was performed by method of excluding all the
included preprinted literatures and method of one-by-
one elimination to verify the stability of the results.
Rates for dichotomous data were analyzed using the
Stata 16.0 (Stata Corp LP, TX, USA) Metaprop package.
Since most studies were of retrospective design and
heterogeneity between studies expected, the random-
effects model was chosen for data synthesis [23]. Odds
Ratio (ORs) and 95% confidence intervals (CIs) were
used for dichotomous variables as effect measures and
were graphically visualized using Forest plots. Besides,
T-statistic using Hartung–Knapp–Sidik–Jonkman
method was performed for the degrees of freedom in
the random-effects analysis, when the number of stud-
ies was < 10 by R version 4.03 (Metafor package) [24].
Heterogeneity across studies was evaluated using the
Cochrane Q test and I2 test (I2 ¼ 100% ((Q-df)/Q). An I2
value of 0–49%, 50–74% and >75% indicated low, mod-
erate or high heterogeneity, respectively [25]. A two-
sided P value < 0.10 was considered statistically signifi-
cant. Subgroup analysis was performed for each indi-
vidual virus. If the number of studies was <9,
publication bias was not investigated. Publication bias
was evaluated with Begg’s test, Egger’s test and
Funnel-plot. Meta-regression analysis was used to find
potential heterogeneity. A two-sided P-value <0.05
except heterogeneity was considered statistically
significant.
Results
Search results and study selection
Our initial search strategy identified 42 papers on SARS,
32 papers on MERS and 125 papers on COVID-19 (199
records) displayed in Figure 1. The search strategy was
listed in Supplementary 1. A further search was then
performed on citation and online preprint servers iden-
tifying 15 further papers, resulting in a total of 214
records. Following a thorough assessment, 58 articles
with 13452 patients were included for quantitative syn-
thesis and further investigation (Tables 1 and 2). Most
COVID-19 studies were performed in Asia (68%, n¼ 21)
[6,26–45], followed by Europe (19%, n¼ 6) [46–51] and
North America (13%, n¼ 4) [52–55]. Most SARS studies
were performed in Asia (88%, n¼ 7) [5,56–61] except
for one study from Canada[62], and almost all the MERS
studies were performed in Saudi Arabia (95%, n¼ 18)
[3,63–79] with the exception of one study from South
Korea. Follow-up duration ranged from 1 to 46months.
The publication years of these studies ranged from
2003 to 2020. All studies on COVID-19 were published
within the first 6 months of 2020.
Quality rating
The quality rating for each study was evaluated by the
NOS (Newcastle-Ottawa scale) (Supplementary Table 1).
The average score of the included studies was 5.6 indi-
cating moderate quality. The average score of studies
for SARS, MERS, and COVID-19 were 5.8, 6.2, and 5.2,
respectively. In domains of comparability, 52 studies
with single arms did not fulfill the selection of the non-
exposed cohort and only six studies [43,45,59,61,71,80]
received scores. The GRADE tool was used to summar-
ize pooled evidence for the main outcomes, as shown
in Supplementary Table 2. Except several subgroup
comparisons were rated as low, the majority of recom-
mendations generated from this systematic review and
meta-analysis were evaluated as very low.
AKI incidence and mortality risk in patients with
coronavirus infection
The overall incidence of AKI was 12.5% (95% CI:
7.6%–18.3%, Heterogeneity I2 ¼ 97.8%, p< 0.001;
Supplementary Figure 1) adjusted for sample size with
an overall mortality rate of 80.9% (95% CI:
57.6%–97.4%, Heterogeneity I2 ¼ 96.1%, p< 0.001,
Supplementary Figure 2). AKI significantly increased the
risk of mortality (OR 5.73, 95% CI 3.75 to 8.77,
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p< 0.00001; I2 ¼ 92%, p< 0.00001, Figure 2) in patients
with coronavirus infection.
The incidence of AKI was 9.0% (95% CI: 4.2%–15.2%)
in patients with COVID-19 but varied from 8.3% to
28.85% in the four studies reporting COVID-19 related
AKI on ICU [81]. The mortality rate of AKI patients with
COVID-19 was 72.3% (95% CI: 47.1%–92.0%) in nine
studies [27–29,32–34,43,45,55]. AKI was associated with
a higher risk of mortality compared with non-AKI
patients (Nine studies [27–29,32–34,43,45,55], OR 5.22,
95% CI 3.39 to 8.04, p< 0.00001; I2 ¼ 94%, p< 0.00001,
Figure 2) in COVID-19 patients. T-statistic was per-
formed to check the stability of this result: t¼ 6.015,
p¼ 0.0003. There was no significant publication bias
(Begg’s test: p¼ 0.251, and Egger’s test: p¼ 0.304).
Funnel plot was nearly symmetrical (Supplementary
Figure 3).
The incidence of AKI was 9.6% (95% CI: 3.9%–17.2%)
in SARS patients. AKI occurred in 51 out of 641 SARS
patients. The mortality rate of AKI patients with SARS
was 98.9% (95% CI: 86.9%–100.0%) in three studies
[56,57,59]. However, AKI itself was not associated with a
significantly higher risk of mortality (three studies
[56,57,60], OR 22.31, 95% CI 0.34 to 1470.81, p¼ 0.15; I2
¼ 95%, p< 0.00001, Figure 2) in these studies. T-statis-
tic was performed to check the stability of this result:
t¼ 1.459, p¼ 0.282.
The incidence of AKI was the highest in MERS, which
was 42.0% (95% CI: 29.8%–54.7%). The mortality rate of
AKI patients with MERS was 100.0% (95% CI:
82.4%–100.0%) based on two studies [3,72]. AKI was
associated with a significantly higher risk of mortality
(Two studies [3,72], OR 8.84, 95% CI 1.37 to 57.15,
p¼ 0.02; I2 ¼ 0%, p¼ 0.80, Figure 2) in MERS patients.
However, T-statistic showed that t¼ 9.202 and
p¼ 0.069.
Urgent-start KRT application in patients with
coronavirus infection
The overall rate of urgent-start KRT use was 8.9% (95%
CI: 5.0%–13.8%, Heterogeneity I2 ¼ 97.2%, p< 0.001,
Figure 1. Flow chart of the diagram. SARS: severe acute respiratory syndrome; MERS: Middle East respiratory syndrome; COVID-
19: novel coronavirus disease 2019.
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Table 1. Summary of the characteristics of the enrolled studies.






















Wong 2003 Retrospective cohort study SARS Hong Kong, China NA 6 15 66.3 ± 13.5 years 1/15 (6.67%) 1/1 (100.00%) 4/15 (26.67%) 4/4 (100.00%)
Gu 2005 Case series SARS Beijing, China NA 8 8 41.9 ± 14.5 years NA NA 0/8 (0%) NA
Chen 2005 Retrospective cohort study SARS Taiwan, China 2 4 30 40 years (range,
12–87 years)
3/30 (10.00%) 2/3 (66.67%) NA NA
Wu 2005 Case-control study SARS Taiwan, China 1 14 60 47 ± 17 years 11/60 (18.33%) NA 0/60 (0%) NA
Farcas 2005 Retrospective cohort study SARS Toronto, Canada 6 19 19 68.8 ± 15.5 years NA NA 0/19 (0%) NA
Chu 2005 Retrospective cohort study SARS Hong Kong, China NA 33 536 53.5 years (range,
34–77 years)
36/536 (6.71%) 33/36 (91.67%) 0/536 (0%) NA
Kwan 2004 Retrospective cohort study SARS Hong Kong, China 4 9 35 58 years (range,
34–74 years)
NA NA 12/35 (34.29%) 3/12 (25.00%)
Peiris 2003 Prospective cohort study SARS Hong Kong, China <1 5 75 39.8 ± 12.2 years NA NA NA NA
Al-Jasser 2019 Retrospective cohort study MERS Saudi Arabia 20 50 249 46.71 ± 17.92 years NA NA 29/249 (11.25%) NA
Assiri 2016 Retrospective cohort study MERS Saudi Arabia 6 21 38 51 years (range,
17–84 years)
NA NA 12/38 (31.58%) 9/12 (75.00%)
Garout 2018 Retrospective cohort study MERS Saudi Arabia 4 39 52 NA NA NA 11/52 (21.15%) 11/11 (100.00%)
Sherbini 2017 Retrospective cohort study MERS Saudi Arabia 2 10 29 45 years (range,
NA)
NA NA 8/21 (27.59%) 8/8 (100.00%）
Shalhoub 2015 Retrospective cohort study MERS Saudi Arabia 1 22 32 NA NA NA 14/32 (43.75%) 14/14 (100.00%）
Hastings 2016 Retrospective cohort study MERS Saudi Arabia 2 NA 78 53 years (range,
NA)
NA NA 11/78 (14.10%) NA
Arabi 2017 Retrospective cohort study MERS Saudi Arabia 37 217 330 58 years (range,
44–69 years)
NA NA 100/330 (30.30%) 80/100 (80.00%)
Assiri 2013 Retrospective cohort study MERS Saudi Arabia 9 28 47 NA NA NA 23/47 (48.93%) 17/23 (73.91%)
Alfaraj 2019 (1) Case series MERS Saudi Arabia 46 0 7 8.04 ± 5.67 years NA NA 1/7 (14.29%) 0/1 (0%）
Alqahtani 2018 Retrospective cohort study MERS Saudi Arabia 26 55 281 NA NA NA 9/281 (3.20%) 6/9 (66.67%)
Alanazi 2019 Retrospective cohort study MERS Saudi Arabia 1 13 48 58 years (range,
29–84 years)
NA NA 10/48 (20.83%) NA
Alfaraj 2019 (2) Retrospective cohort study MERS Saudi Arabia 47 78 314 48 ± 17.3 years NA NA NA NA
Al-Tawfiq 2014 Case-Control study MERS Saudi Arabia 2 13 17 62 years (range,
14–87 years)
NA NA 5/17 (29.41%) NA
Arabi 2014 Case series MERS Saudi Arabia 8 7 12 59 years (range,
36–83 years)
7/12 (58.33%) 7/7 (100%) 8/12 (66.67%) NA
Cha 2015 Retrospective cohort study MERS South Korea 2 5 30 54 ± 20.7 years 8/30 (26.67%) NA 3/30 (10.00%) NA
Ghamdi 2016 Retrospective cohort study MERS Saudi Arabia 11 19 51 54 years (IQR 36.5–58) NA NA 14/51 (27.45%) 8/14 (57.14%)
Khalid I 2016 Retrospective cohort study MERS Saudi Arabia 1 9 14 54 years (range,
23–79 years)
5/14 (35.71%) NA 6/14 (42.85%) 3/6 (50%)
Khalid M 2014 Case series MERS Saudi Arabia NA 3 6 58.8 ± 24.7 years 3/6 (50.00%) 3/3 (100%) 0/6 (0%) NA
Omrani 2014 Retrospective cohort study MERS Saudi Arabia 19 34 44 NA 22/44 (50.00%) NA 11/44 (25.00%) NA
Ma 2020 Retrospective cohort study COVID-19 Wuhan, China 1 6 41 66 years (IQR 55–81) NA NA 37/41 (90.24%) 6/37 (16.22%)
Richardson
2020
Retrospective cohort study COVID-19 New York, America 1 553 5700 63 years (IQR 52–75) 1307/
5700 (22.93%)
347/1307 (66.35%) 454/5700 (7.96%) NA
Chen N 2020 Retrospective cohort study COVID-19 Wuhan, China <1 11 99 55.5 ± 13.1 years 3/99 (3.03%) NA 0/99 (0%) NA
Lu 2020 Retrospective cohort study COVID-19 Shanghai, China 1 1 265 NA 1/265 (0.37%) NA 5/265 (1.89%) NA
Wang D 2020 Retrospective cohort study COVID-19 Wuhan, China <1 6 138 56 years (IQR 42–68) 5/138 (3.62%) NA 4/138 (2.89%) NA
Chen T 2020 Retrospective cohort study COVID-19 Wuhan, China 1 113 274 62 years (IQR 44–70) 29/274 (10.58%) 28/29 (96.55%) 4/274 (1.46%) 4/5 (80%)
Xu 2020 Retrospective cohort study COVID-19 Zhejiang, China <1 0 62 41 years (IQR 32–52) NA NA 1/62 (1.61%) NA
Huang 2020 Retrospective cohort study COVID-19 Wuhan, China 1 6 41 49 years (IQR 41–58) 3/41 (21.42%) NA 0/41 (0%) NA
Diao 2020 Retrospective cohort study COVID-19 Wuhan, China 2 NA 85 NA 23/85 (27.06%) NA 5/85 (5.88%) NA
Cao 2020 Retrospective cohort study COVID-19 Wuhan, China 1 17 102 54 years (IQR 37–67) 20/102 (19.61%) 15/20 (75.00%) 4/102 (3.92%) 3/4 (75.00%)
Arentz 2020 Retrospective cohort study COVID-19 Washington, America 1 11 21 70 years (range,
43–92 years)
4/21 (19.04%) NA 12/21 (57.14%) NA
Cheng 2020 Prospective cohort study COVID-19 Wuhan, China 1 113 701 63 years (IQR 50–71) 36/701 (5.14%) 16/35 (45.71%) 14/698 (2.01%) NA
Guan 2020 Retrospective cohort study COVID-19 China 1 15 1099 47 years (IQR 35–58) 6/1099 (0.55%) NA 8/1099 (0.73%) NA
Shi 2020 Retrospective cohort study COVID-19 Wuhan, China 1 57 416 64 years (range,
21–95 years)














Supplementary Figure 4) but only one [56] study
reported the use of urgent-start KRT in SARS patients
with a rate of 1.87% and no deaths.
Urgent-start KRT-treated patients with coronavirus
infection had an overall mortality of 80.7% (95% CI:
58.8%–96.6%, Heterogeneity I2 ¼ 92.9%, p< 0.001,
Supplementary Figure 5). The use of urgent-start KRT
was significantly associated with increased mortality
(OR 3.43, 95% CI 2.02 to 5.82, p< 0.00001; I2 ¼ 97%,
p< 0.00001, Figure 3) although this applied only to
patients with MERS and COVID-19.
So far, 13 studies [6,26,27,29,31–35,39,40,45,55] have
reported the rate of urgent-start KRT use (3.4%, 95% CI:
1.9%–5.4%) in hospitalized patients with COVID-19. The
mortality rate of urgent-start KRT-treated patients with
COVID-19 was 74.2% (95% CI: 45.8%–95.5%) in six stud-
ies [27,29,32–34,55]. The use of urgent-start KRT was
associated with a higher risk of mortality compared
with non-KRT patients (Six studies [27,29,32–34,55], OR
3.04, 95% CI 1.77 to 5.22, p< 0.0001; I2 ¼ 95%,
p< 0.00001, Figure 3) in COVID-19. T-statistic showed
that t¼ 4.597 and p¼ 0.006. Sensitivity analysis by
removal of Richardson et al.’s study [55] resulted in a
10% reduction of heterogeneity for mortality.
Seven studies [3,63,65,67,72,77,80] reported the
highest rate of urgent-start KRT use (35.0%, 95% CI:
16.8%–55.4%) in hospitalized patients with MERS. The
mortality rate of urgent-start KRT patients with MERS
was 85.5% (95% CI: 78.9%–91.2%) in four studies
[65,67,72,80]. The use of urgent-start KRT was also asso-
ciated with a higher risk of mortality in MERS patients
(Four studies [65,67,72,80], OR 4.56, 95% CI 1.49 to
13.90, p¼ 0.008; I2 ¼ 93%, p< 0.00001, Figure 3). T-stat-
istic showed that t¼ 3.365 and p¼ 0.044.
Pre-dialysis CKD prevalence and mortality risk in
patients with coronavirus infection
The overall prevalence of CKD was 14.2% (95% CI:
9.6%–19.6%, Heterogeneity I2 ¼ 97.6%, p< 0.001,
Supplementary Figure 6). The mortality rate of CKD
patients with coronavirus infection was 65.4% (95% CI:
46.3%–82.7%, Heterogeneity I2 ¼ 87.3%, p< 0.001,
Supplementary Figure 7). CKD significantly increased
the risk of mortality (OR 1.97, 95% CI 1.56 to 2.49,
p< 0.00001; I2 ¼ 65%, p< 0.0001, Figure 4) in patients
with coronavirus infection.
The prevalence of CKD comorbidity was 11.0% (95%
CI: 5.6%–17.8%) in COVID-19 patients with an associ-
ated mortality rate of 38.7% (95% CI: 16.8%–62.7%) in
eight studies [27–29,33,34,37,38,51]. CKD was associ-
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compared with non-CKD patients with COVID-19 (Seven
studies [27–29,33,34,37,38], OR 2.42, 95% CI 1.61 to
3.64, p< 0.0001; I2 ¼ 35%, p¼ 0.16, Figure 4). T-statistic
showed that t¼ 4.605 and p¼ 0.004. Sensitivity analysis
by removal of a single-study showed that Cao et al.’s
study [34] contributed about 22% of the heterogeneity.
The prevalence of CKD was 4.4% (95% CI:
0.0%–19.0%) in SARS patients. The mortality rate of
CKD patients with SARS was 46.5% (95% CI:
20.6%–73.2%) in two studies [57,61]. CKD was not asso-
ciated with a significantly higher risk of mortality in
SARS patients although this analysis was based on only
two studies (Two studies [57,61], OR 2.06, 95% CI 0.46
to 9.21, p¼ 0.35; I2 ¼ 70%, p¼ 0.07, Figure 4). T-statistic
showed that t¼ 0.998 and p¼ 0.501.
The prevalence of CKD was 23.8% (95% CI:
15.8%–32.7%) in MERS patients. The mortality rate of
CKD patients with MERS was very high, i.e. 83.6% (95%
Table 2. Summary of the characteristics of the enrolled studies in patients with ESKD.












Wong 2003 SARS 4/15 (26.67%) (3 PD; 1 HD) 4/4 (100.00%)
(PD:3; HD:1)
NA NA NA NA
Gu 2005 SARS 0/8 (0%) NA NA NA NA NA
Chen 2005 SARS NA NA NA NA NA NA
Wu 2005 SARS 0/60 (0%) NA NA NA NA NA
Farcas 2005 SARS 0/19 (0%) NA NA NA NA NA
Chu 2005 SARS 0/536 (0%) NA 10/536 (1.87%) NA NA NA
Kwan 2004 SARS 12/35 (34.29%) (8 PD; 4 HD) 3/12 (25.00%) NA NA 12/700 (1.71%) 3/12 (25.00%)
Peiris 2003 SARS NA NA NA NA NA NA
Al-Jasser 2019 MERS NA NA 33/249 (13.25%) 25/33 (75.76%) NA NA
Assiri 2016 MERS 12/38 (31.58%) (dialysis:12) 9/12 (75.00%) NA NA 12/377 (3.18%) 9/12 (75.00%)
Garout 2018 MERS NA NA NA NA NA NA
Sherbini 2017 MERS NA NA NA NA NA NA
Shalhoub 2015 MERS 8/32 (25.00%) 8/8 (100.00%） NA NA NA NA
Hastings 2016 MERS 11/78 (14.10%) NA NA NA 11/22 (50.00%) NA
Arabi 2017 MERS NA NA 161/330 (48.79%) 131/161 (81.37%) NA NA
Assiri 2013 MERS NA NA NA NA NA NA
Alfaraj 2019 (1) MERS 1/7 (14.29%) 0/1 (0%） NA NA NA NA
Alqahtani 2018 MERS 7/281 (2.49%) 4/7 (57.14%) NA NA NA NA
Alanazi 2019 MERS NA NA NA NA NA NA
Alfaraj 2019 (2) MERS NA NA NA NA NA NA
Al-Tawfiq 2014 MERS 5/17 (29.41%) (dailysis:5) NA NA NA NA NA
Arabi 2014 MERS 2/12 (16.67%) (kidney
transplant:1; dialysis:1)
NA 7/12 (58.33%) NA NA NA
Cha 2015 MERS NA NA 3/30 (10.00%) 3/3 (100%) NA NA
Ghamdi 2016 MERS 14/51 (27.45%) 8/14 (57.14%) NA NA NA NA
Khalid I 2016 MERS 3/14 (21.43%) (HD:3) 3/3 (100.00%) 5/14 (35.71%) NA NA NA
Khalid M 2014 MERS 0/6 (0%) NA 3/6 (50.00%) 3/3 (100%) NA NA
Omrani 2014 MERS 0/44 (0%) NA 22/44 (50.00%) NA NA NA
Ma 2020 COVID-19 37/41 (90.24%) 6/37 (16.22%) NA NA 37/230 (16.09) 6/37 (16.22%)
Richardson 2020 COVID-19 186/5700 (3.26%) NA 225/5700 (3.95%） 78/225 (96.30%) NA NA
Chen N 2020 COVID-19 0/99 (0%) NA 9/99 (9.09%) NA NA NA
Lu 2020 COVID-19 NA NA 2/265 (0.75%) NA NA NA
Wang D 2020 COVID-19 NA NA 2/138 (1.45%) NA NA NA
Chen T 2020 COVID-19 NA NA 3/274 (1.09%) 3/3 (100%) NA NA
Xu 2020 COVID-19 NA NA NA NA NA NA
Huang 2020 COVID-19 NA NA 3/41 (21.42%) NA NA NA
Diao 2020 COVID-19 NA NA NA NA NA NA
Cao 2020 COVID-19 NA NA 6/102 (5.88%) 5/6 (83.33%) NA NA
Arentz 2020 COVID-19 2/21 (9.52%) NA NA NA NA NA
Cheng 2020 COVID-19 NA NA NA NA NA NA
Guan 2020 COVID-19 NA NA 9/1099 (0.82%) NA NA NA
Shi 2020 COVID-19 NA NA 2/416 (0.48%) NA NA NA
Wang L 2020 COVID-19 5/116 (4.31%) 0/5 (0%) NA NA NA NA
Yang 2020 COVID-19 0/52 (0%) NA 9/52 (17.31%) 8/9 (88.89%) NA NA
Pei 2020 COVID-19 NA NA 6/333 (17.14%) NA NA NA
Xiong 2020 COVID-19 NA NA NA NA 154/7154 (2.15%) 41/131 (31.30%)
Luo 2020 COVID-19 NA NA 39/403 (9.68%) 16/39 (41.03%) NA NA
Zhou 2020 COVID-19 NA NA 10/191 (5.24%) 10/10 (100%） NA NA
Albalate 2020 COVID-19 NA NA NA NA 37/90 (41.11%) 6/37 (16.22%)
Valeri 2020 COVID-19 NA NA NA NA NA 18/59 (30.51%)
Chen M 2020 COVID-19 NA NA NA NA NA NA
Jung 2020 COVID-19 NA NA NA NA 14/582 (2.41%) 2/14 (14.29%)
Arslan 2020 COVID-19 NA NA NA NA 7/602 (1.16%) 0/7 (0%)
Alberici 2020 COVID-19 NA NA NA NA 94/643 (14.62%) 27/94 (28.72%)
Goicoechea 2020 COVID-19 NA NA NA NA 36/282 (12.77%) 11/36 (30.56%)
Dudreuilh 2020 COVID-19 NA NA NA NA 34/664 (5.12%) NA
Trujillo 2020 COVID-19 51/51 (100%) 13/51 (25.49%) NA NA NA 7/25 (28.00%)
Manganaro 2020 COVID-19 130/156 (83.33) NA NA NA 102/3280 (3.11%) NA
Fisher 2020 COVID-19 NA NA NA NA NA 32/114 (28.07%)
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CI: 69.4%–94.7%). As for the nine articles
[63,65,66,68,69,73,74,76,79] describing the prognosis of
197 CKD patients versus 677 non-CKD patients with
MERS, pooled analysis of the mortality revealed a sig-
nificantly higher risk of mortality in MERS patients with
CKD (OR 1.78, 95% CI 1.36 to 2.34, p< 0.0001; I2 ¼ 72%,
p¼ 0.0004, Figure 4). T-statistic showed that t¼ 3.244
and p¼ 0.012. There was no significant publication bias
(Begg’s test: p¼ 0.118, and Egger’s test: p¼ 0.075) but
the Funnel plot was not so symmetrical (Supplementary
Figure 8).
ESKD prevalence and mortality risk in patients
with coronavirus infection
The overall prevalence of ESKD was 16.4% (95% CI:
7.2%–27.9%, Heterogeneity I2 ¼ 98.2%, p< 0.001,
Supplementary Figure 9). The overall mortality rate of
ESKD patients with coronavirus infection was 51.7%
(95% CI: 27.0%–76.1%, Heterogeneity I2 ¼ 83.3%,
p< 0.001, Supplementary Figure 10). Overall analysis
showed that ESKD significantly increased the risk of
mortality (OR 1.81, 95% CI 1.44 to 2.27, p< 0.00001; I2
¼ 0%, p¼ 0.62, Figure 5) in patients with corona-
virus infection.
The prevalence of ESKD was 30.9% (95% CI:
4.6%–66.8%) in the COVID-19-related studies. The mor-
tality rate of ESKD patients with COVID-19 was 17.6%
(95% CI: 8.2%–29.2%). Compared with non-ESKD
patients, ESKD was not associated with a higher risk of
mortality although this was based on two studies (two
studies [37,38], OR 1.46, 95% CI 0.21 to 10.08, p¼ 0.70;
I2 ¼ 0%, p¼ 0.87, Figure 5) in SARS-CoV-2. T-statistic
showed that t¼ 2.339 and p¼ 0.257.
The prevalence of ESKD was 4.4% (95% CI:
0.0%–19.0%) in SARS related studies. The mortality rate
of ESKD patients with SARS was 46.5% (95% CI:
20.6%–73.2%). ESKD was also not associated with a
higher risk of mortality (Two studies [57,61], OR 2.06,
95% CI 0.46 to 9.21, p¼ 0.35; I2 ¼ 70%, p¼ 0.07, Figure
5) in SARS patients. T-statistic showed that t¼ 0.999
and p¼ 0.500.
The prevalence of ESKD was 13.8% (95% CI:
5.1%–25.2%) included MERS related studies. The mortal-
ity rate of ESKD patients with MERS was the highest:
78.1% (95% CI: 51.1%–97.6%). The pooled analysis of
Figure 2. Mortality risk of AKI in three types of coronavirus diseases compared with non-AKI. AKI: acute kidney injury; SARS:
severe acute respiratory syndrome; MERS: Middle East respiratory syndrome; COVID-19: novel coronavirus disease 2019.
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the mortality revealed a significantly higher risk of mor-
tality in MERS patients with ESKD (Five studies
[63,68,74,76,79], OR 1.79, 95% CI 1.41 to 2.27,
p< 0.00001; I2 ¼ 0%, p¼ 0.57, Figure 5). T-statistic
showed that t¼ 5.682 and p¼ 0.005.
Patients on chronic hemodialysis and the
occurrence of coronavirus infection
The overall incidence of coronavirus infection was 7.7%
(95% CI: 4.9%–11.1%, Heterogeneity I2 ¼ 97.2%,
p< 0.001, Supplementary Figure 11) with a mortality
rate of 26.4% (95% CI: 20.6%–32.6%, Heterogeneity I2 ¼
51.6%, p< 0.001, Supplementary Figure 12).
The incidence of COVID-19 was 8.0% (nine studies
[30,38,42,44,46–50], 95% CI: 4.7%–12.0%) in hemodialy-
sis patients with a mortality rate of 25.7% (nine studies
[30,38,42,44,46,49–51,53], 95% CI: 21.3%–30.3%). The
incidence of SARS was 1.7% (95% CI: 0.9%–3.0%) based
on a single study [61] with a mortality rate of 25.0%
(95% CI: 5.5%–57.2%). The incidence of MERS was 3.6%
(95% CI: 1.8%–5.9%) from two studies [74,75] in hemo-
dialysis patients with an associated mortality rate of
75.0% (one study [74], 95% CI: 42.8%–94.5%).
Sensitivity analysis and meta-regression analysis
We further conducted sensitivity analysis to evaluate
the influence of case series and preprinted literatures
on the stability of results. First, the results maintained
significance after excluding all the preprinted literatures
included in the pooled analysis [27,28,38,39,41].
Second, the results also maintained stable by excluding
the literatures included in the pooled analysis one by
one. Moreover, too few studies were left in each sub-
group after excluding all the case series, because this
type of study occupied a relatively large proportion
(about 50%). Thus, we kept the case series with number
of patients reported equal or greater than 5 cases, and
rated the quality of these literatures referring to a gen-
erally recommended standard [17]. Meta-regression
analysis was used to find potential heterogeneity in pri-
mary results. However, different ethnicities and study
types did not contribute significantly to the heterogen-
eity in four results (P all > 0.05).
Discussion
The COVID-19 pandemic that is currently raging around
the world is causing major disruption to health systems
[82]. As a member of the coronavirus family [2], COVID-
Figure 3. Mortality risk of urgent-start KRT use in three types of coronavirus diseases. Urgent-start KRT: urgent-start renal
replacement therapy; MERS: Middle East respiratory syndrome; COVID-19: novel coronavirus disease 2019.
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19 together with SARS and MERS lead to severe acute
respiratory symptoms [83], as well as extrapulmonary
disease [84]. Although the kidney is commonly affected,
its contribution to patient mortality and morbidity is
only belatedly being recognized. Compared with similar
systematic reviews [85,86] that had been published so
far, our research explored the impact of kidney-related
events on the prognosis of patients in the face of cor-
onavirus abuse from a more comprehensive and in-
depth perspective. We conducted this systematic
review to investigate the incidence of AKI, the increased
risk to patients with preexisting CKD, ESKD or urgent-
start KRT and differences in kidney outcomes for all
three recent coronavirus pandemics.
Our results indicate that AKI occurs in around one-
tenth of the infected study population with an overall
mortality rate of 80.9%. The incidence of AKI was high-
est in MERS patients, while being similar between
COVID-19 and SARS patients. The incidence in ICU-
treated patients varied between 8.3% and 28.85% [81].
Compared to COVID-19 patients, the mortality rate was
higher in SARS and MERS patients although fewer stud-
ies were reported for the SARS [56,57,60] and MERS
[3,72] subgroups. AKI was associated with a significantly
higher mortality in COVID-19 and MERS. In the SARS
subgroup, this did not reach statistical significance pos-
sibly due to the small number of studies included. The
incidence of urgent-start KRT use in coronavirus
Figure 4. Mortality risk of non-dialytic preexisting CKD in three types of coronavirus diseases compared with non-CKD. CKD:
chronic kidney disease; SARS: severe acute respiratory syndrome; MERS: Middle East respiratory syndrome; COVID-19: novel cor-
onavirus disease 2019.
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infected patients with AKI was 8.9% with an associated
mortality of 80.7%. This probably reflects the fact that
AKI patients requiring urgent-start KRT are generally
more critically ill, likely to need ventilatory support or
extracorporeal membrane oxygenation (ECMO) [87].
Many dialysis modalities [88–90], including CRRT, high-
volume hemofiltration, plasma exchange, plasma
adsorption and acute peritoneal dialysis have been
reported, mostly as case reports or small case series. A
consensus recommendation regarding the optimal dia-
lysis modality, timing, dosage and duration for manage-
ment of AKI in coronavirus diseases is urgently needed.
Our analysis also showed that the presence of CKD
or ESKD was significantly associated with increased
mortality. The overall prevalence of ESKD was higher
than that of preexisting CKD, possibly due to different
number of studies being enrolled for each
analysis. Patients with MERS had the highest mortality
in prevalent patients with CKD or ESKD. Several
studies have reported on virus prevalence and
mortality in patients on prevalent hemodialysis
[30,38,42,44,46–51,53,54,61,74,75]. The incidence of
COVID-19 was 8.0% in routine hemodialysis patients,
which was higher than SARS or MERS, but similar to the
general population. The mortality rate for this subgroup
was 25.7%, which was nearly the same as SARS but
much less than with MERS (75%). Our analysis confirms
that prevalent patients with CKD or on urgent-start KRT
are at much higher risk of infection and of subsequent
worse outcomes. Epidemic prevention measures must
be strengthened especially in dialysis centers [91].
Specific measures that could be introduced include the
setting up of isolation areas for dialysis centers, wearing
personal protective equipment, tracking and isolating
contacts and environmental disinfection. For infected
patients, continuous bedside dialysis has been success-
fully deployed [92].
Our study had several limitations. First, we combined
studies with a certain degree of heterogeneity, owing
to the differences in the study design, sample size and
population characteristics of the studies included. The
specific reasons were as follows: (1) inclusion of case
control study and case series can introduce bias to the
result, which may lead to the high heterogeneity; (2)
Figure 5. Mortality risk of preexisting ESKD in three types of coronavirus diseases compared with non-ESKD. ESKD: end-stage
renal disease; SARS: severe acute respiratory syndrome; MERS: Middle East respiratory syndrome; COVID-19: novel coronavirus dis-
ease 2019.
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the number of infected patients enrolled in the
included articles varied widely; (3) the inconsistent defi-
nitions of AKI or CKD or ESKD could have accounted for
the variation of our results on AKI; (4) differences in the
timing of outbreaks, geographical locations, ages, gen-
ders, habits, cares, and treatments may also contribute
to the high heterogeneity; (5) the total sample size of
SARS and MERS related studies was much smaller than
COVID-19. Second, sampling bias may have contributed
to part of our analysis when less than five cases were
excluded. Third, renal function follow-up to assess renal
recovery was not available. Fourth, several case series
(about 8.62%) were included in our study, which could
reduce the strength of the generated evidences. Then
we tried to do the sensitivity analysis excluding all the
case series, but found too few studies left. Also shown
with the GRADE tool, the level of evidences generated
in this study were low or very low; thus, more future
high-quality researches are urged to confirm
our results.
In conclusion, the kidney is commonly affectedly in
patients with COVID-19, SARS and MERS. Renal events
including AKI, preexisting CKD, and ESKD significantly
increased the risk of mortality. Prevalent patients on
urgent-start KRT also have an increased risk of infection
and mortality. Routine hemodialysis patients were also
at high risk of infection and mortality.
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